Sofinnova Partners led the round, investing €4million (EUR) alongside returning investors, with ALK-Abello investing €2million (EUR). In addition to an equity sharehold in DBV Technologies, ALK-Abello will also have a seat on DBV Technologies’ Board of Directors. In return, ALK-Abello will provide its expertise in preclinical and clinical product development to DBV.
DBV Technologies Chairman and CEO Jean-Francois Biry said: “We are delighted to have attracted such an experienced corporate investor. We are sure their expertise in clinical development will be invaluable for the development of our pipeline, including our upcoming Phase I peanut allergy trials. Also we are very pleased to be financially sponsored again by our leading financial investor, Sofinnova Partners.”
ALK-Abello President and CEO Jens Bager said:”We are very pleased to bring our long lasting expertise in Allergy to this promising Biopharmaceutical company and its innovative therapeutic approach towards Peanuts Allergy.”
About DBV Technologies - www.dbv-technologies.com
DBV Technologies, based in Paris,France is a speciality pharma company specialising in the development of non-invasive epicutaneous diagnostics and immunotherapies for allergy diagnosis and treatment. The Company is lead by CEO Jean-François Biry and was born out of the experience of Doctor Pierre-Henri Benhamou, a paediatrician specialising in gastro-enterology, allergosis and nutrition, and Bertrand Dupont, a qualified engineer from the Arts et Métiers Institute. DBV’s lead product, Diallertest® Milk, is on sale in France and other countries for the diagnosis of cow’s milk protein allergy.
Founded in 2002, DBV Technologies has 16 employees(2008) and is based in the Pépinière Paris Santé Cochin, in Paris’ 14th arrondissement.
About VIASKIN® DBV Technologies’ globally patented VIASKIN® technology is a unique delivery system which retains active compounds on a carrier using electrostatic forces only. The delivery platform allows active compounds to be presented to the epidermis of the skin without breaking the blood-skin barrier. In not breaking the blood-skin barrier, DBV Technologies’ allergen diagnosis and specific immunotherapy treatments avoid inducing systemic shock – one of the most serious concerns associated with current desensitisation therapies. DBV’s VIASKIN® technology is in development for the treatment of allergies through Epicutaneous Specific Immunotherapy(EPIT) and for the administration of vaccines. The company is currently seeking partnerships in these areas. DBV’s lead product, Diallertest® Milk, utilises VIASKIN® technology and is on sale in France and other countries for the diagnosis of cow’s milk protein allergy.
